11/5/2026

speaker
Conference Operator
Operator

Good afternoon, ladies and gentlemen, and welcome to the Skin Health Systems 2026 Third Quarter Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, November 5th, 2026. I would now like to turn the conference over to Norberto Aja, Investor Relations.

speaker
Norberto Aja
Investor Relations

Thank you, operator, and good afternoon, everyone. Thank you for joining Skins Health Systems' third quarter 2026 conference call. We released our results earlier this afternoon, which can be found on our corporate website at SkinsHealthSystems.com. Joining me on the call today is Skins Health Systems President and Chief Executive Officer, Pedro Malha, along with their Chief Financial Officer, Mike Monahan. Before we begin, I want to remind everyone of the company's safe harbor language. Management may make forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including guidance and underlying assumptions. Forward-looking statements are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to defer materially. Listeners are cautioned not to place a new reliance on any forward-looking statements. For further discussion of risks related to our business, please refer to the risk factors contained in the company's filings with Securities and Exchange Commission. In addition, this call will present non-GAAP financial measures. Management uses adjusted EBITDA and other non-GAAP measures, supplemental measures, to evaluate operating performance and to facilitate period-to-period comparisons. These non-GAAP measures should be considered in addition to and not as a substitute for financial information prepared in accordance with GAAP. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measure is available in the earnings press release, which was furnished to the SEC, as well as available on our website. Following management's prepared remarks, we will open the call for a question and answer session. With that, I would now like to turn the call over to our president and CEO, Pedro Malha. Please go ahead, Pedro.

speaker
Pedro Malha
President and Chief Executive Officer

Thank you, Norberto, and good afternoon, everybody. Let me start with a central message from this quarter. We are making progress on the things that matter the most, stabilizing the hydrofacial business and improving the economics of the company. and at the same time, we are developing new opportunities for growth. To be clear, the work isn't done. Equipment sales remain challenging, particularly in EMEA. And utilization in our install base is still below where it should be. But we are making good progress against our plan. And the third quarter results provide tangible evidence that we are operating from a stronger foundation than a year ago. Our third quarter revenue was $69.2 million towards the upper end of our $65 million to $70 million guidance range, meaning that our quarterly revenue declined 2.1% year over year, which is a meaningful improvement from the declines of 7.8% in the second quarter and 6.7% in the first quarter. And importantly, Global consumables returned to growth, up 1.2% on a year-over-year comparison, while equipment remained the primary headwind. But the rate of the overall revenue decline has moderated significantly. At the same time, the earnings profile of the business continues to improve. On a gap basis, growth margin was 68.2%, operating income was approximately $5 million and net loss was approximately $1 million. We delivered positive gap operating income for the second conservative quarter and adjusted gross margin was 71.8, our third consecutive quarter above 70%. Adjusted EBITDA was $13.4 million. Some of our quarterly bottom line outperformance benefit from one time item and expense timing. But we are also seeing the benefits of better margins, tighter cost management, and a more efficient operating model. The priority now is to sustain those improvements while returning revenue to growth. Looking across our regions, we are seeing encouraging signs in the Americas. which grew 1.4%, with consumables growing 4.3% on a year-over-year comparison. EMEA remained challenged, with revenues dying approximately 12% on a year-over-year comparison, reflecting pressure in delivery systems, particularly in Germany, where execution has been below expectations. To address this, we have strengthened regional leadership and we are taking actions to improve field execution and customer engagement. In APEC, revenue declined approximately 4% on a year-over-year comparison, primarily reflecting the transition in Australia and New Zealand to a distributor model. So while our performance varies across markets, we know where the pressure is and we are taking actions to address it. Let me turn now to our three strategic priorities and the progress we are making in building a stronger, more sustainable growth business. Our first priority is strengthening the core hydrofacial franchise. We have a fantastic global brand, a deep customer relationship, but we need to translate those advantages into better commercial execution. So over the past year, We organized our commercial teams, strengthened accountability, and invested in better training, processes, and selling tools. We are also taking a more targeted approach to customers, with a great emphasis on hydrofacial clinical differentiation and the economic value it creates for providers. Additionally, we are expanding our relationships with corporate and multi-location accounts, where we see opportunities to broaden our installed-based and increased treatment volumes. And during the quarter, we introduced a U.S. rental program to address one of the key barriers to equipment adoption, the upfront capital investment. It's still early, but the objective is to make hydrofacial more accessible and bringing more providers into the hydrofacial ecosystem and support long-term relationships with them. We are also advancing our next-generation hydrofacial platform, currently targeted for 2028, with the goal of improving clinical outcomes, provider workflow, and overall treatment experience. On competition, we haven't seen a meaningful change in intensity from what we discussed last quarter. But our strategy isn't simply to compete on price. It's to strengthen our differentiation, improve commercial execution, and deliver greater value to our providers. Our second strategic priority is getting more value from the hydrofacial installed base. Throughout the years, we have built a substantial global network of providers, and that represents one of our biggest competitive advantage. But placing a system is only the beginning of the customer relationship. The real opportunity lies in helping providers perform more treatments, increase utilization, and generate more recurring consumables revenue. We saw encouraging progress in the quarter, with global consumables growing 1.2% on a year-over-year comparison, and the Americas consumables returning to growth for the first time this year, supported by strong signature consumables performance plus a hydrofacial relaunch and other commercial initiatives. But consumable revenues per systems remained below last year, and we believe we can do more to improve productivity across the install base. And that's an important part of our innovation strategy, bringing providers clinically differentiated treatments that address real consumer needs and create more reasons for consumers to come back. So in September, we introduced our treatment enhancers, the HydroGlo pre-extraction peel, and the HydroLock HA biocellulose mask. And in October, we launched a new booster, HydroClear, for blemish-prone skin, which in clinical evaluation showed that a series of HydroClear treatments produce a 38% mean reduction in total blemishes. So these launches are a good example of the direction we're taking with innovation. More targeted, clinical supported products that address specific customer needs. Our hydrosculpt relaunch is another good example of how we are working to expand how providers can use their existing hydrofacial system in the scalp and in the hair health. Equally important is our work in helping providers turn this innovation into greater treatment volumes and we are doing this with education programs like Hydrofacial Impact, which was built to help providers attract more customers and increase repeat visits and improve their treatment economics. The point isn't simply to launch more products. It's to make the systems already in the market more productive. And if we execute well, we can create a meaningful recurring revenue opportunity without relying entirely on new equipment placements. Our third strategic priority is to build a broader skin health business. Our ambition is not to be limited to one product or one category. We want to participate in attractive, high-growth segments of the aesthetic market and offer providers complementary treatments and give consumers more reasons to engage with our brands. Skin stylist is a good example of that strategy in play. Microneedling is an attractive, and growing segments that complements hydrofacial. And SkinStylus gives us a strong platform to compete in that market, offering both microneedling and nano-channel treatments. SkinStylus consumables grew 39% year over year this quarter. And very recently, we expanded SkinStylus into six key European markets, leveraging our existing international commercial infrastructure. We are also making good progress towards a planned introduction of another complementary device in 2027 with more details to come. But what's important is strategically is that we believe we already have the customer relationships, the commercial infrastructure, and the clinical credibility that we can leverage those advantages across a broader portfolio. That's how we can build a stronger company. not by moving away from what made it successful, but by building on it. So let me bring all of this together. The revenue decline has narrowed significantly. Overall, consumables have returned to growth, margins are substantially stronger, and we're making progress on the commercial and innovation initiatives that can drive the next phase of our business. We still have work to do on the equipment sales, Utilization, and EMEA. But when I look at skin health systems, I see a much bigger opportunity than the one we are capturing today. We have a strong global brand, a substantial install base, a more efficient operating model, and an expanding portfolio. Our job now is to turn those advantages into sustainable growth through better execution in the core business, greater productivity from our installed base, and a disciplined expansion into new categories. And that is exactly that what we are focusing on delivering. And with that, I'll just turn the call over to Mike.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API